Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Aug 31, 2016 BOSTON, Aug. 31, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 2016 Wells Fargo Healthcare Conference on Wednesday, September 7th, 2016 at 10:30 a.m. E.T. The conference is being held at the Westin Bosto...
PDF
Aug 9, 2016 BOSTON, Aug. 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company's recent activities. "ZIOPHARM had a very productive first half, with the achievement of pipeline and corporate m...
PDF
Aug 4, 2016 Favorable Long Term Follow-up in Two Trials with Patients Receiving Autologous CAR-T cells and Allogeneic CAR-T cells Potential benefits of Sleeping Beauty approach include reduced costs, complexity, and improved tolerability BOSTON, Aug. 04, 2016 ...
PDF
Aug 2, 2016 BOSTON, Aug. 02, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it will host a conference call and webcast slide presentation to discuss financial results for the quarter ended June 30, 2016 and provide a mid-year corporate update on Tuesday, August 9, 2016 at 4:30 PM ET. ...
PDF
Jul 20, 2016 BOSTON, July 20, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), due to recent developments, today issued the following statement clarifying market speculation regarding the Company's financing activity:  "The Company currently has no plans to access the capital markets in a ...
PDF
Jul 19, 2016 BOSTON, July 19, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.  ...
PDF
Jul 15, 2016 BOSTON, July 15, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding the Company's ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma:"This Phase I s...
PDF
Jul 12, 2016 BOSTON, July 12, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer...
PDF
Jun 30, 2016 GERMANTOWN, Md. and BOSTON, June 30, 2016 (GLOBE NEWSWIRE) -- Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and ...
PDF
Jun 27, 2016 BOSTON, June 27, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the successful completion of enrollment in the first and second dosing cohorts as well as the initiation of enrollment in a third cohort in the Company's ongoing multi-center Phas...
PDF
Page:
1
... NextLast